Teitl: A prospective, observational study to evaluate quality of life, patient reported outcomes, and safety in patients with relapsing-remitting Multiple Sclerosis who are being treated with Alemtuzumab (Lemtrada) in routine clinical practice

Arianwyr
Sanofi

Prif Ymchwiliwr

Robertson, Neil


Manylion y Prosiect

Gwerth net y ffigur a ddyfarnwyd i Brifysgol Caerdydd: £1,456.00

Dyddiad dechrau: 22.12.2016

Dyddiad gorffen: 31.12.2019


Diweddarwyd y tro diwethaf ar 2024-24-03 am 04:43